What the FDA labels say about taking them together
Amphotericin b and cyclophosphamide
Cyclophosphamide's FDA label (Frindovyx) of August 26, 2026 names amphotericin b in its drug interactions section; the amphotericin b label PlainMeds reads does not name cyclophosphamide. The cyclophosphamide label: “… pulmonary toxicity ● Amiodarone ● G-CSF, GM-CSF Increased nephrotoxicity ● Amphotericin B ● Indomethacin:”
Check it at the source: the amphotericin b FDA label on DailyMed (effective June 3, 2025, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.); the cyclophosphamide FDA label on DailyMed (effective January 19, 2026, Amneal Pharmaceuticals LLC).
What does the amphotericin b label say about cyclophosphamide?
Amphotericin b's label (effective June 3, 2025) does not name cyclophosphamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Amphotericin B), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective June 3, 2025 (SPL set 2b2f3ff5-9d62-4ad2-8eac-1181e5911513), via openFDA; the full label on DailyMed
What does the cyclophosphamide label say about amphotericin b?
Frindovyx label (AVYXA Pharma, LLC, August 26, 2026), drug interactionsACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone ● G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor) Increased nephrotoxicity ● Amphotericin B ● Indomethacin:
Cyclophosphamide label (Eugia US LLC, April 21, 2025), drug interactionsToxicity: Increased nephrotoxicity; Drugs: Amphotericin B Indomethacin: Acute water intoxication has been reported with concomitant use of indomethacin
Source: FDA drug label (Frindovyx, NDA210852), AVYXA Pharma, LLC, effective August 26, 2026 (SPL set 5ad8ea65-4c98-487a-9c8d-df778765ec5e), via openFDA
Source: FDA drug label (Cyclophosphamide, NDA210735), Eugia US LLC, effective April 21, 2025 (SPL set 3c1eb470-0bba-457d-94e3-b9508f0d398a), via openFDA
Source: FDA drug label (Cyclophosphamide), Amneal Pharmaceuticals LLC, effective January 19, 2026 (SPL set 520bfe39-dfd5-4a20-9a37-80078afded0d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amphotericin b | Cyclophosphamide | |
|---|---|---|
| Labeled for | Fungal infections | Leukemia, lymphoma and myeloma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.67 per capsule 50 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once